For example, Seladelpar's clinical trial has been discontinued due to atypical histological findings.[52] What is more, PPAR dual/pan agonists, including Lanifibranor and Saroglitazar, have been developed for treating NAFLD.[52] Apart from the beneficial effects of these agonists, adverse events such as impaired kidney function, rhabdomyolysis, weight gain, and cardiovascular dysfunctions have also been reported.[52, 53] Therefore, addressing the resolution of NAFLD remains a challenging task, requiring further concerted efforts. This evidence concerns the gene PPARA and rhabdomyolysis.